Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.07 USD | -0.70% | -1.95% | -45.48% |
Financials (USD)
Sales 2024 * | 968M | Sales 2025 * | 1.09B | Capitalization | 2.81B |
---|---|---|---|---|---|
Net income 2024 * | 113M | Net income 2025 * | 224M | EV / Sales 2024 * | 2.28 x |
Net cash position 2024 * | 606M | Net cash position 2025 * | 863M | EV / Sales 2025 * | 1.79 x |
P/E ratio 2024 * |
26.5
x | P/E ratio 2025 * |
13
x | Employees | 598 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
Latest transcript on ACADIA Pharmaceuticals Inc.
1 day | -0.70% | ||
1 week | -1.95% | ||
Current month | -7.68% | ||
1 month | -8.81% | ||
3 months | -38.13% | ||
6 months | -26.45% | ||
Current year | -45.48% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Sanjeev Pathak
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.73% | 1 M€ | 0.00% | - | |
1.24% | 16 M€ | -9.75% | ||
0.26% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 17.07 | -0.70% | 988,365 |
24-04-17 | 17.19 | +0.64% | 1,027,814 |
24-04-16 | 17.08 | +1.12% | 978,294 |
24-04-15 | 16.89 | -1.46% | 1,112,106 |
24-04-12 | 17.14 | -1.55% | 1,296,092 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.48% | 2.81B | |
-1.82% | 41.35B | |
+44.25% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- ACAD Stock